General

Survodutide is a dual GLP-1 and glucagon receptor agonist under investigation for the treatment of obesity and related metabolic conditions. It exerts its effects by promoting satiety, enhancing fat oxidation, and increasing energy expenditure, leading to significant weight loss. Early clinical studies suggest Survodutide’s potential as a promising agent in managing obesity and improving metabolic health in scientific and educational peptide research studies.

Chemical Properties